Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02481154 · ClinicalTrials.gov registry record · Phase 1
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
A Phase 1 study of Glioma, sponsored by Institut de Recherches Internationales Servier.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 9
- Study locations
NCT02481154: Completed Phase 1 study of Glioma, sponsored by Institut de Recherches Internationales Servier.
NCT02481154 is a Phase 1 study of Glioma that has completed, run by Institut de Recherches Internationales Servier. The registered enrollment target is 95 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (55% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02481154, a Phase 1 study of Glioma, has completed, sponsored by Institut de Recherches Internationales Servier.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in Gliomas, that harbor an IDH1 and/or IDH2 mutation.
Conditions Studied
Interventions
- DRUG AG881
Study Locations (9)
California
- UCLA Oncology Center - Los Angeles
- University of California San Francisco - San Francisco
Texas
- UT Southwestern Medical Center - Dallas
- MD Anderson Cancer Center - Houston
Florida
- University of Miami - Miami
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University Medical Center - Durham
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2015-06 |
| Est. Completion | 2024-06-19 |
| Phase | Phase 1 |
What the finished NCT02481154 record still lists
NCT02481154 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which AG881 is the first listed.
NCT02481154 lists 9 locations in 7 states (California, Texas, Florida).
Frequently Asked Questions
What is clinical trial NCT02481154 about?
NCT02481154 is a clinical study titled "Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation". This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in Gliomas, that harbor an IDH1 and/or IDH2 mutation.
What is the current status of trial NCT02481154?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2015-06. Estimated completion is 2024-06-19.
What conditions does trial NCT02481154 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT02481154?
The interventions under investigation include: AG881 (DRUG).
Who is sponsoring clinical trial NCT02481154?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02481154 being conducted?
This trial has 9 study locations across California, Florida, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02481154's enrollment target sits among peer trials
95 24th of 87 higher than 64 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia